These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 16137750)

  • 41. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
    Lheureux S; Shaw PA; Karakasis K; Oza AM
    Gynecol Oncol; 2015 Aug; 138(2):235-7. PubMed ID: 26072440
    [No Abstract]   [Full Text] [Related]  

  • 43. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
    Mahajan NN
    Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
    [No Abstract]   [Full Text] [Related]  

  • 45. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
    Kauff ND; Barakat RR
    Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
    [No Abstract]   [Full Text] [Related]  

  • 46. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A genetic epidemiological study of carcinoma of the fallopian tube.
    Aziz S; Kuperstein G; Rosen B; Cole D; Nedelcu R; McLaughlin J; Narod SA
    Gynecol Oncol; 2001 Mar; 80(3):341-5. PubMed ID: 11263928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.
    Zweemer RP; van Diest PJ; Verheijen RH; Ryan A; Gille JJ; Sijmons RH; Jacobs IJ; Menko FH; Kenemans P
    Gynecol Oncol; 2000 Jan; 76(1):45-50. PubMed ID: 10620440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation.
    Finch A; Metcalfe KA; Chiang J; Elit L; McLaughlin J; Springate C; Esplen MJ; Demsky R; Murphy J; Rosen B; Narod SA
    Psychooncology; 2013 Jan; 22(1):212-9. PubMed ID: 21913283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.
    Quillin JM; Boardman CH; Bodurtha J; Smith T
    Gynecol Oncol; 2001 Oct; 83(1):168-70. PubMed ID: 11585435
    [No Abstract]   [Full Text] [Related]  

  • 53. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
    Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
    [No Abstract]   [Full Text] [Related]  

  • 55. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
    Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
    Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
    Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
    Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
    Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.